MedTrace Logo

Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer

NCT00027534 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2014-09-08

No results posted yet for this study

Summary

RATIONALE: Vaccines made from a person's white blood cells that have been treated in the laboratory may make the body build an immune response to kill tumor cells.

PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have advanced or metastatic cancer.

Conditions

Interventions

BIOLOGICAL

TRICOM-CEA(6D)

dendritic cells loaded with TRICOM-CEA(6D)

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Michael Morse, MD

    lead OTHER

Principal Investigators

  • Herbert K. Lyerly, MD · Duke Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-01-31
Primary Completion
2007-10-31
Completion
2007-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00027534 on ClinicalTrials.gov